Brokerage sentiment across the pharmaceutical and emerging workspace sectors remains broadly optimistic, with firms such as Citi and Choice Institutional Equities highlighting robust growth drivers and improving earnings visibility for key players.Citi continues to back large-cap pharma names like Lupin and Sun Pharma, citing strong momentum in their US businesses, healthy product pipelines, and structural margin levers that are expected to
Buy, Sell or Hold: Citi maintains buy on largecap pharma stocks like Lupin & Sun Pharma
